🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Myeloma Paper of the Day: Phase 3 IRAKLIA study shows Isatuximab (+Pom/dex) w/ on-body delivery system shows similar efficacy & pharmacokinetic non-inferiority versus Isa-iv/Pom/dex w/ no unexpected safety signal and lower infusion reaction rate: pubmed.ncbi.nlm.nih.gov/40459178/. #mmsm

#Myeloma Paper of the Day: MIDAS study of MRD-guided consolidation strategy in pts eligible for ASCT finds those who were MRD-negative @ 10-5 post-induction % w/ pre-maintenance MRD- status at 10-6 sensitivity was not higher with ASCT vs. Isa-KRd: pubmed.ncbi.nlm.nih.gov/40459097/. #mmsm

#Myeloma Paper of the Day: Study of long-term (≥5-yr) remission & survival post-cilta cel finds median OS 60.7 mos; 32/97 pts alive & progression-free for ≥5 years; had lower tumor burden, more naïve T-cells, higher Hgb & plts, higher E:T ratio: pubmed.ncbi.nlm.nih.gov/40459151/. #mmsm

#Myeloma Paper of the Day: Review of monoclonal gammopathy of cutaneous significance (MGCS), a paraproteinemia w/ serious cutaneous sequelae which warrants co-management w/ hematology & treatment to address underlying Ig- or plasma cell disorder: pubmed.ncbi.nlm.nih.gov/40466947/. #mmsm

#Myeloma Paper of the Day: Comparison of patient-reported frailty phenotype & International Myeloma Working Group frailty index shows fair agreement; frail pts by PRFP had higher tx side effects, dz symptoms, worse future perspectives & body image: pubmed.ncbi.nlm.nih.gov/40472573/. #mmsm

#Myeloma Paper of the Day: Single-cell proteomic analysis reveals myeloma heterogeneity & dynamics of immune μenvironment in precursor & advanced states w/ progression marked by shifts from CD45+/CD138-lo populations in precursors to CD45-/CD138-hi: pubmed.ncbi.nlm.nih.gov/40482292/. #mmsm

#Myeloma Paper of the Day: Eagerly awaited new high-risk IMWG definition: 1. del 17p w/ >20% clonal frac &/or TP53 mut; 2. t(4;14), t(14;16), t(14;20) w/ 1q+ &/or del 1p32; 3. monoallelic del 1p32 w/ 1q+ or biallelic del 1p32; 4. β2 ≥5.5 & nl SCr: pubmed.ncbi.nlm.nih.gov/40489728/. #mmsm

#Myeloma Paper of the Day: Biallelic antigen escape may be mechanism of resistance to anti-CD38 antibodies; L153H & C275Y decreased binding affinity & ADCC of daratumumab & isatuximab while a 3rd, R140G, conferred selective resistance to dara only: pubmed.ncbi.nlm.nih.gov/40493883/. #mmsm

#Myeloma Paper of the Day: GEM12 phase III trial of BUMEL (n=230) vs. MEL200 (n=228) conditioning w/ ASCT after induction w/ 6 VRD cycles followed by two VRD consolidation cycles finds median PFS 89 vs. 73.1 months in the two arms; HR 0.89, P= 0.3: pubmed.ncbi.nlm.nih.gov/40499010/. #mmsm

Myeloma Paper of the Day, June 12th, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma CancerWorld

#Myeloma Paper of the Day: German analysis of 343 triple-class exposed relapsed/refractory pts who received ide-cel or cilta-cel finds cilta w/ higher CR rate (61% vs. 39%) & improved response conversion w/ more CRs after starting from <CR pre-CAR: pubmed.ncbi.nlm.nih.gov/40504993/. #mmsm

Myeloma Paper of the Day, June 13th, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center Nico Gagelmann Marc S. Raab oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #RRMM #Myeloma #CART CancerWorld

#Myeloma Paper of the Day: Retrospective study of AL #amyloidosis pts (n=130) w/ liver involvement finds median time to hepatic response (HepR) 21.5 mos; baseline ALP ≥4xULN predicted HepR; HemR, kappa isotype & front-line ASCT also predicted HepR: pubmed.ncbi.nlm.nih.gov/40509545/. #mmsm

Myeloma Paper of the Day, June 14th, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center Mayo Clinic Vincent Rajkumar Shaji Kumar oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma #AL #Amyloidosis

#Myeloma Paper of the Day: Prospective study of immunogenicity to SARS-CoV-2 boosters in myeloma & #Waldenström finds factors associated w/ lower response were: hypogamma, lymphopenia, anti-CD38, corticosteroid in MM; anti-CD20 or BTKi therapy 4 WM: pubmed.ncbi.nlm.nih.gov/40472329/. #mmsm

#Myeloma Paper of the Day: EMMY study of patients retreated w/ anti-CD38 shows median PFS of 5.1 months (23.6 in pts sensitive to anti-CD38 vs. 4.6 if non-sensitive; median OS 17.3 months for all pts (14.8 mos in non-sensitive vs. NR in sensitive): pubmed.ncbi.nlm.nih.gov/40518372/. #mmsm

Myeloma Paper of the Day, June 16th, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma #EmmyCohortStudy CancerWorld

#Myeloma Paper of the Day: Post-hoc analysis of VTE on BENEFIT study finds 6-mo. cumulative rate 4.8% (0.8% on low-dose DOACs, 5.6% on prophylactic heparin, 9.8% on aspirin); only 1 VTE beyond 6-month period; 1/3 pts w/ VTE had no prophylaxis: pubmed.ncbi.nlm.nih.gov/40523501/. #mmsm

#Myeloma Paper of the Day: Phase 2 study of dara/thal/dex in relapsed and/or refractory MM finds median PFS 16 months (9.4 if thal/len/pom refractory), ORR 82% (64% VGPR or better, 25% CR or better, 13% sCR), median DOR 19 mos, median OS 32.5 mos: pubmed.ncbi.nlm.nih.gov/40527888/. #mmsm

#Myeloma Paper of the Day: Optical genome mapping reveals complex cytogenetic abnormalities in myeloma beyond those detected by karyotyping or FISH, including deletions, insertions, duplications, inversions, and translocations: pubmed.ncbi.nlm.nih.gov/40534500/. #mmsm